Closing The Books On Taxol: GAO Report Fuels Sen. Wyden’s Pricing Push
Executive Summary
NIH should consider the cost of new therapies to Medicare when negotiating technology transfers for taxpayer-funded research, Sen. Ron Wyden (D-Ore.) maintained in response to a June 4 1GAO report on the National Institutes of Health's collaboration with Bristol for the oncologic agent Taxol
You may also be interested in...
Reimbursement News, In Brief
Sen. Wyden questions Xeljanz pricing at Senate hearing and Sen. Nelson wants new OIG review of Medicaid versus Medicare drug rebates. GAO compares VA, DoD drug purchasing in report.
Norvir “March In” Would Deter Future NIH/Industry Collaboration, Bayh Warns
Abbott has the support of one of the authors of the federal technology transfer laws in its fight to prevent the National Institutes of Health from "marching in" on its Norvir patents
Norvir “March In” Would Deter Future NIH/Industry Collaboration, Bayh Warns
Abbott has the support of one of the authors of the federal technology transfer laws in its fight to prevent the National Institutes of Health from "marching in" on its Norvir patents